Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,369 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Recruiting Phase 2 Interventional

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

NCT06207799
View directory record Official record
Conditions
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions
Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lean Body Mass Response to Higher-protein Diets During Winter Military Training

NCT02327208
View directory record Official record
Conditions
Body Weight
Interventions
Control, Protein, Carbohydrate
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Oxalate-Driven Host Responses in Kidney Stone Disease

NCT05417568
View directory record Official record
Conditions
Kidney Stones
Interventions
Low Oxalate Diet, High Oxalate Diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Albuterol Spiromax® in Subjects With Asthma

NCT01698320
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 17, 2026, 4:29 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NCT05624996
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
476
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

NCT04940390
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebo
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
127
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Flavonoids on Gut Permeability in Cyclists

NCT03427879
View directory record Official record
Conditions
Gut Permeability, Gut Inflammation
Interventions
Low flavonoid beverage, High flavonoid beverage
Drug
Lead sponsor
Utah State University
Other
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 17, 2026, 4:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Small Extracellular Vesicles and Insulin Action

NCT05933707
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolically Healthy Obesity, Obesity, Metabolically Benign
Interventions
People with Metabolically Unhealthy Obesity - Low Calorie Diet
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT02634606
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition

NCT00982462
View directory record Official record
Conditions
Infant Development
Interventions
Docosahexaenoic acid (DHA) and arachidonic acid (ARA), Corn oil placebo
Dietary Supplement
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
351 Days to 379 Days
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 17, 2026, 4:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
FTX-101, Placebo
Drug
Lead sponsor
Find Therapeutics
Industry
Eligibility
18 Years to 59 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 17, 2026, 4:29 AM EDT
Terminated Phase 3 Interventional

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

NCT00005090
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 17, 2026, 4:29 AM EDT
Active, not recruiting Phase 2 Interventional

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 4:29 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Researching Economical Adjuvants to Cancer Therapy

NCT07305259
View directory record Official record
Conditions
Healthy Participants
Interventions
Beta-glucan, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 17, 2026, 4:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation

NCT03907501
View directory record Official record
Conditions
Human Microbiome
Interventions
Synbiotic, Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lipoprotein Effects of Substituting Beef Protein for Carbohydrate

NCT00852267
View directory record Official record
Conditions
Healthy, Cardiovascular Disease, Atherogenic Dyslipidemia
Interventions
High Carbohydrate, High Saturated Fat Diet, Low Carbohydrate, High Saturated Fat Diet, Low Carbohydrate, Low Saturated Fat Diet
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Sargramostim Use in COVID-19 to Recover Patient Health

NCT04707664
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Sargramostim, Placebo
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adverse Metabolic Effects of Dietary Sugar

NCT02548767
View directory record Official record
Conditions
Chronic Disease of Cardiovascular System, Type 2 Diabetes, Obesity
Interventions
high fructose corn syrup, aspartame, Energy-balanced diet, Ad libitum diet
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Davis, California • Sacramento, California • Vallejo, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 17, 2026, 4:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

NCT00005095
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Interventions
Ca-125, screening questionnaire administration, Surgery
Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2040
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

NCT00071799
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Azacitidine, Physician Choice
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

New Treatment for Alcohol and Nicotine Dependence

NCT01182766
View directory record Official record
Conditions
Alcohol Dependence, Nicotine Dependence
Interventions
Low-Dose Topiramate, Placebo, High-Dose Topiramate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
La Jolla, California • Houston, Texas • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

NCT00004157
View directory record Official record
Conditions
Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, recombinant interleukin-11
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 17, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT01363128
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma, CD20 Positive, Childhood Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 17, 2026, 4:29 AM EDT